MedTrace Logo

Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01103609 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-11-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics and Pharmacodynamics of Warfarin in T2DM patients.

Conditions

Interventions

DRUG

Warfarin

Oral tablet od on Day 4

DRUG

Placebo

Oral tablet bd, stepwise increased

DRUG

AZD1656

Oral tablet bd, stepwise increased

Sponsors & Collaborators

Principal Investigators

  • Stanko Skrtic · AstraZeneca

  • James Ritter, Prof · Quintiles Drug Research Unit

  • Mirjana Kujacic · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103609 on ClinicalTrials.gov